Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...

VGA039 is a first-in-class monoclonal antibody therapy with a novel mechanism of action that targets Protein S, thereby ...

("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ...

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) ...

"ArkBio commences Phase II study of AK0610 for RSV prevention" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery ...